Iovance Biotherapeutics, Inc.
- Last sale
- Nov 12, 2026 · -5.57%
- Market cap
- $3.53B
- 462.66M shares
- Filings
- 1,026
Q3 2026+60.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+41.0% FY25 yoy
- $3.53B
- —
- 9.3×
- 4.3×
- -6.12%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $263,502,000 | reported | |
| FY 2024 | 2024-12-31 | $164,070,000 | reported | |
| FY 2023 | 2023-12-31 | $1,189,000 | reported | |
| FY 2018 | 2018-12-31 | $0 | reported | |
| FY 2017 | 2017-12-31 | $0 | reported | |
| FY 2016 | 2016-12-31 | $0 | reported | |
| FY 2015 | 2015-12-31 | $0 | reported | |
| FY 2014 | 2014-12-31 | $0 | reported | |
| FY 2013 | 2013-12-31 | $0 | reported | |
| FY 2012 | 2012-12-31 | $0 | reported | |
| FY 2011 | 2011-12-31 | $0 | reported | |
| FY 2010 | 2010-12-31 | $0 | reported |
Segments
LineFY2025ShareChange
Federal income tax$259.01M98%+60.8%
Non-US$4.49M1.7%+48.3%
Total$263.50M
Biological products, except diagnostic substances
Iovance Biotherapeutics, Inc. is the 21st largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
TARSTarsus Pharmaceuticals, Inc.$451.4M146.7%14.7%$3.8BIMCRImmunocore Holdings plc$400.0M29.0%8.9%$1.6BKRYSKrystal Biotech, Inc.$389.1M33.9%52.6%$9.1BADPTAdaptive Biotechnologies Corp$277.0M54.8%21.5%$4.8BVCELVericel Corp$276.3M16.5%6.0%$2.9B
IOVAIovance Biotherapeutics, Inc. (this company)$263.5M60.6%148.4%$3.5B
VXRTVaxart, Inc.$237.3M726.7%6.9%$117.0MRGNXRegenxbio Inc.$170.4M104.5%113.8%$531.0MDNAGinkgo Bioworks Holdings, Inc.$170.2M25.1%183.8%$658.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Iovance Biotherapeutics, Inc. · CIK 1425205 · Engraved from SEC EDGAR